Published in Women's Health Weekly, May 18th, 1998
"This is an advancement for people who suffer from urinary incontinence because current therapies on the market require administration two to four times a day," said Jack V. Talley, Penwest Pharmaceuticals Co. "The once-daily dosing schedule of controlled release oxybutynin makes it more convenient to administer, especially for patients who suffer during the night."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly